Now in its 50th year, the non-profit Israel Cancer Research Fund is the largest funder of cancer research in Israel after the Israeli government with over $100 million in research funded since inception . ICRF’s research has led to key oncology drug discoveries including Velcade, Gleevec and Doxil. Since October 7, 2023 Israeli scientists have faced myriad challenges including their family and themselves serving in the army, foreign students leaving country and rampant antisemitism at conferences and from publications. During the 12-Day war, Iranian missiles destroyed labs and research at the Weizmann institute and days later key scientific discoveries were made. The family of the late chairman of the Chicago chapter of ICRF is generously matching gifts made by 9/1 and all gifts support the cancer research of Israeli scientists during a most challenging period. Thank you!